Comparing methods collecting mucosal secretions and detecting SARS-CoV-2 spike IgA in three laboratories across three countries
Several mucosal vaccines are in development, and consistent methodologies assessing mucosal IgA are crucial for evaluation across clinical trials.
Age and Latent Cytomegalovirus Infection Do Not Affect the Magnitude of De Novo SARS-CoV-2-Specific CD8+ T Cell Responses
Immunosenescence, age-related immune dysregulation, reduces immunity upon vaccinations and infections.
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies
The evolution of the antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacted by the nature and number of antigenic exposures.
Prevalence and clinical relevance of viraemia in viral respiratory tract infections: a systematic review
SARS-CoV-2 viraemia was linked to memory problems and worsened quality of life. Viraemia was associated with signatures denoting dysregulated host responses.
News
Policy & Recommendations
Joint Action on REspiratory Diseases (JARED) launched
A new joint action focusing on tackling chronic respiratory diseases was recently launched. Backed by the EU4Health programme, the 3-year initiative aims to improve lung health across Europe through innovative digital health technologies.
Targeting the SARS-CoV-2 reservoir in long COVID
There are no approved treatments for post-COVID-19 condition, a debilitating disease state following SARS-CoV-2 infection that is estimated to affect tens of millions of people.
Variants and vaccines impact nasal immunity over three waves of SARS-CoV-2
Viral variant and host vaccination status impact infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), yet how these factors shift cellular responses in the human nasal mucosa remains uncharacterized.
SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study
After surviving Coronavirus Disease 2019 (COVID-19), some people develop symptoms known as post-acute sequelae of COVID-19 (PASC). PASC is an emerging phenomenon yet to be fully understood, and identifying risk factors has been challenging.